Literature DB >> 35085183

Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients.

Andrew H Karaba1, Xianming Zhu2, Sarah E Benner2, Olivia Akinde2, Yolanda Eby2, Kristy H Wang1, Sharada Saraf3, Jacqueline M Garonzik-Wang4, Sabra L Klein1,5, Justin R Bailey1, Andrea L Cox1,5,6, Joel N Blankson1, Christine M Durand1, Dorry L Segev4, William A Werbel1, Aaron A R Tobian2.   

Abstract

BACKGROUND: Solid organ transplant recipients (SOTRs) are at increased risk for severe COVID-19 and exhibit lower antibody responses to SARS-CoV-2 vaccines. This study aimed to determine if prevaccination cytokine levels are associated with antibody response to SARS-CoV-2 vaccination.
METHODS: A cross-sectional study was performed among 58 SOTRs before and after two-dose mRNA vaccine series, 35 additional SOTRs before and after a third vaccine dose, and comparison to 16 healthy controls (HCs). Antispike antibody was assessed using the IgG Euroimmun ELISA. Electrochemiluminescence detection-based multiplexed sandwich immunoassays (Meso Scale Diagnostics) were used to quantify plasma cytokine and chemokine concentrations (n = 20 analytes) and compare concentrations between SOTRs and HCs, stratified by ultimate antibody response to the vaccine using Wilcoxon-rank-sum test with false discovery rates computed to correct for multiple comparisons.
RESULTS: In the study population, 100% of HCs, 59% of SOTRs after 2 doses and 63% of SOTRs after 3 doses had a detectable antibody response. Multiple baseline cytokines were elevated in SOTRs versus HCs. There was no significant difference in baseline cytokine levels between SOTRs with high versus low-titer antibodies after 2 doses of vaccine. However, as compared with poor antibody responders, SOTRs who went on to develop a high-titer antibody response to a third dose of vaccine had significantly higher prethird dose levels of several innate immune cytokines including IL-17, IL-2Ra, IL-6, IP-10, MIP-1α, and TNF-α (false discovery rates < 0.05).
CONCLUSIONS: A specific inflammatory profile may be associated with developing higher antibodies in response to a third dose of SARS-CoV-2 vaccine in SOTRs.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35085183      PMCID: PMC8942602          DOI: 10.1097/TP.0000000000004057

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  28 in total

Review 1.  IP-10 is highly involved in HIV infection.

Authors:  Jie Lei; Xiaowan Yin; Hong Shang; Yongjun Jiang
Journal:  Cytokine       Date:  2018-11-22       Impact factor: 3.861

Review 2.  The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor.

Authors:  Jan Damoiseaux
Journal:  Clin Immunol       Date:  2020-07-01       Impact factor: 3.969

3.  Cytokine production patterns and antibody response to measles vaccine.

Authors:  Inna G Ovsyannikova; Karlene C Reid; Robert M Jacobson; Ann L Oberg; George G Klee; Gregory A Poland
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

4.  A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients.

Authors:  Andrew H Karaba; Xianming Zhu; Tao Liang; Kristy H Wang; Alex G Rittenhouse; Olivia Akinde; Yolanda Eby; Jessica E Ruff; Joel N Blankson; Aura T Abedon; Jennifer L Alejo; Andrea L Cox; Justin R Bailey; Elizabeth A Thompson; Sabra L Klein; Daniel S Warren; Jacqueline M Garonzik-Wang; Brian J Boyarsky; Ioannis Sitaras; Andrew Pekosz; Dorry L Segev; Aaron A R Tobian; William A Werbel
Journal:  Am J Transplant       Date:  2022-01-18       Impact factor: 8.086

5.  Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.

Authors:  Kizzmekia S Corbett; Martha C Nason; Britta Flach; Matthew Gagne; Sarah O'Connell; Timothy S Johnston; Shruti N Shah; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Charlene McDanal; Joseph R Francica; Barbara Flynn; Kai Wu; Angela Choi; Matthew Koch; Olubukola M Abiona; Anne P Werner; Juan I Moliva; Shayne F Andrew; Mitzi M Donaldson; Jonathan Fintzi; Dillon R Flebbe; Evan Lamb; Amy T Noe; Saule T Nurmukhambetova; Samantha J Provost; Anthony Cook; Alan Dodson; Andrew Faudree; Jack Greenhouse; Swagata Kar; Laurent Pessaint; Maciel Porto; Katelyn Steingrebe; Daniel Valentin; Serge Zouantcha; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Renee van de Wetering; Seyhan Boyoglu-Barnum; Kwanyee Leung; Wei Shi; Eun Sung Yang; Yi Zhang; John-Paul M Todd; Lingshu Wang; Gabriela S Alvarado; Hanne Andersen; Kathryn E Foulds; Darin K Edwards; John R Mascola; Ian N Moore; Mark G Lewis; Andrea Carfi; David Montefiori; Mehul S Suthar; Adrian McDermott; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Robert A Seder
Journal:  Science       Date:  2021-09-17       Impact factor: 47.728

6.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

Authors:  Kizzmekia S Corbett; Barbara Flynn; Kathryn E Foulds; Joseph R Francica; Seyhan Boyoglu-Barnum; Anne P Werner; Britta Flach; Sarah O'Connell; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Hanne Andersen; David R Martinez; Amy T Noe; Naomi Douek; Mitzi M Donaldson; Nadesh N Nji; Gabriela S Alvarado; Darin K Edwards; Dillon R Flebbe; Evan Lamb; Nicole A Doria-Rose; Bob C Lin; Mark K Louder; Sijy O'Dell; Stephen D Schmidt; Emily Phung; Lauren A Chang; Christina Yap; John-Paul M Todd; Laurent Pessaint; Alex Van Ry; Shanai Browne; Jack Greenhouse; Tammy Putman-Taylor; Amanda Strasbaugh; Tracey-Ann Campbell; Anthony Cook; Alan Dodson; Katelyn Steingrebe; Wei Shi; Yi Zhang; Olubukola M Abiona; Lingshu Wang; Amarendra Pegu; Eun Sung Yang; Kwanyee Leung; Tongqing Zhou; I-Ting Teng; Alicia Widge; Ingelise Gordon; Laura Novik; Rebecca A Gillespie; Rebecca J Loomis; Juan I Moliva; Guillaume Stewart-Jones; Sunny Himansu; Wing-Pui Kong; Martha C Nason; Kaitlyn M Morabito; Tracy J Ruckwardt; Julie E Ledgerwood; Martin R Gaudinski; Peter D Kwong; John R Mascola; Andrea Carfi; Mark G Lewis; Ralph S Baric; Adrian McDermott; Ian N Moore; Nancy J Sullivan; Mario Roederer; Robert A Seder; Barney S Graham
Journal:  N Engl J Med       Date:  2020-07-28       Impact factor: 91.245

7.  Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.

Authors:  Victoria G Hall; Victor H Ferreira; Terrance Ku; Matthew Ierullo; Beata Majchrzak-Kita; Cecilia Chaparro; Nazia Selzner; Jeffrey Schiff; Michael McDonald; George Tomlinson; Vathany Kulasingam; Deepali Kumar; Atul Humar
Journal:  N Engl J Med       Date:  2021-08-11       Impact factor: 91.245

8.  Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.

Authors:  William A Werbel; Brian J Boyarsky; Michael T Ou; Allan B Massie; Aaron A R Tobian; Jacqueline M Garonzik-Wang; Dorry L Segev
Journal:  Ann Intern Med       Date:  2021-06-15       Impact factor: 25.391

9.  Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.

Authors:  Nassim Kamar; Florence Abravanel; Olivier Marion; Chloé Couat; Jacques Izopet; Arnaud Del Bello
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

10.  Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.

Authors:  Victoria G Hall; Victor H Ferreira; Matthew Ierullo; Terrance Ku; Tina Marinelli; Beata Majchrzak-Kita; Anila Yousuf; Vathany Kulasingam; Atul Humar; Deepali Kumar
Journal:  Am J Transplant       Date:  2021-08-04       Impact factor: 9.369

View more
  3 in total

1.  Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.

Authors:  Jane C Figueiredo; Fred R Hirsch; Lawrence H Kushi; Wendy N Nembhard; James M Crawford; Nicholas Mantis; Laurel Finster; Noah M Merin; Akil Merchant; Karen L Reckamp; Gil Y Melmed; Jonathan Braun; Dermot McGovern; Samir Parekh; Douglas A Corley; Namvar Zohoori; Benjamin C Amick; Ruofei Du; Peter K Gregersen; Betty Diamond; Emanuela Taioli; Carlos Sariol; Ana Espino; Daniela Weiskopf; Alba Gifoni; James Brien; William Hanege; Marc Lipsitch; David A Zidar; Ann Scheck McAlearney; Ania Wajnberg; Joshua LaBaer; E Yvonne Lewis; Raquel A Binder; Ann M Moormann; Catherine Forconi; Sarah Forrester; Jennifer Batista; John Schieffelin; Dongjoo Kim; Giulia Biancon; Jennifer VanOudenhove; Stephanie Halene; Rong Fan; Dan H Barouch; Galit Alter; Swetha Pinninti; Suresh B Boppana; Sunil K Pati; Misty Latting; Andrew H Karaba; John Roback; Rafick Sekaly; Andrew Neish; Ahnalee M Brincks; Douglas A Granger; Amy B Karger; Bharat Thyagarajan; Stefani N Thomas; Sabra L Klein; Andrea L Cox; Todd Lucas; Debra Furr-Holden; Kent Key; Nicole Jones; Jens Wrammerr; Mehul Suthar; Serre Yu Wong; Natalie M Bowman; Viviana Simon; Lynne D Richardson; Russell McBride; Florian Krammer; Meenakshi Rana; Joshua Kennedy; Karl Boehme; Craig Forrest; Steve W Granger; Christopher D Heaney; Maria Knight Lapinski; Shannon Wallet; Ralph S Baric; Luca Schifanella; Marcos Lopez; Soledad Fernández; Eben Kenah; Ashish R Panchal; William J Britt; Iñaki Sanz; Madhav Dhodapkar; Rafi Ahmed; Luther A Bartelt; Alena J Markmann; Jessica T Lin; Robert S Hagan; Matthew C Wolfgang; Jacek Skarbinski
Journal:  Open Forum Infect Dis       Date:  2022-04-27       Impact factor: 4.423

2.  Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19.

Authors:  Entao Li; Shen Wang; Wenwen He; Jun He; Luogeng Liu; Xiaotuan Zhang; Songtao Yang; Feihu Yan; Yuwei Gao; Bin Liu; Xianzhu Xia
Journal:  Front Microbiol       Date:  2022-05-24       Impact factor: 6.064

3.  Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.

Authors:  Narayan Prasad; Shyam Bihari Bansal; Brijesh Yadav; Neha Manhas; Deependra Yadav; Sonam Gautam; Ravishankar Kushwaha; Ankita Singh; Dharmendra Bhadauria; Monika Yachha; Manas Ranjan Behera; Anupama Kaul
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.